Sonic Healthcare Ltd (ASX: SHL) Share Price and News

Mr Wilks has a background in chartered accounting and investment banking and was previously a partner in a private investment bank. He has held directorships in several public companies and is currently a Non-executive Director of Silex Systems Limited (since 1988), a listed company divested by Sonic in 1996

Prof Compton has senior executive experience in healthcare services. He is currently Adjunct Professor in Management (Healthcare Leadership) at Macquarie University (Macquarie Business School), Non-executive Director of The Hospitals Contribution Fund of Australia and Non-executive Chairman of not-for-profit organisations St Luke Care and the Order of St John (St John Ambulance). His previous experience includes Chief Executive Officer of each of St Luke Care, Immune Systems Therapeutics Limited and the Royal Flying Doctor Service of Australia. He was also Chief Executive Officer and Managing Director of the formerly companies SciGen Limited and Alpha Healthcare Limited. Prof Compton has also held several non-executive director roles, including as Non-executive Chairman of Next Science Limited from May 2021 (Non-executive Director from 2018) to 23 August 2023, and for formerly Independent Practitioner Network Limited (2004-2008). He was also Chairman of the Woolcock Institute of Medical Research, Non-executive Director of Macquarie University Hospital and Chairman and Chancellor of St John Ambulance Australia (having served as a volunteer for more than 50 years). In recognition of his work in the healthcare sector and his service to the community, he was awarded the Centenary Medal of the Commonwealth of Australia, appointed by Her Majesty the Queen as a Knight in the Order of St John in 2004 and as Bailiff Grand Cross in 2017, and was appointed as a Member of the Order of Australia (AM) in January 2010.

Mr Mitchell was Chief Financial Officer and Company Secretary of Cochlear Limited (until March 2017). He is currently on the boards of Fisher and Paykel Healthcare Corporation (Non-executive Director from November 2018, Non-executive Chair from August 2024) and Sigma Healthcare Limited (Non-executive Director from February 2023). He was formerly a Non-executive Director of Osprey Medical, Inc. (from July 2012 until May 2022) and QBiotics Group Limited (from November 2017 to May 2023). He has also performed roles with several industry and government committees. He is a member of the Risk Management Committee.

Prof Crowe current positions include Non-executive Director of Avita Medical, Inc. (from January 2016), and Emeritus Professor of Medicine at Monash University, Melbourne (from 2020). She was a Non-executive Director of St Vincent Health Australia Ltd from January 2013 until October 2021. She retired from Burnet Institute as Associate Director in 2018 following a 30-year research career, having played an integral role in Burnet development as a global research organisation. She retired as Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne in 2019 after 35 years of service. She has served as a Member of the Prime Minister Science Engineering and Innovation Council (India/China Working Group), as Head of the World Health Organization (WHO) Regional Reference Laboratory for HIV Resistance Testing and as an HIV advisor to WHO for 25 years. She was appointed as an Officer of the Order of Australia (AO) in 2020, in recognition of her distinguished service to health and aged care administration, clinical governance, biomedical research, and to education. She is Chair of the Risk Management Committee.

Prof Bennett is a paediatrician with over 40 years of healthcare industry experience across the private, public and not-for-profit sectors. Professor Bennett is an experienced non-executive director in profit and social enterprises. She was Convenor of the Champions of Change Coalition STEM and Health Group for gender equality until April 2026 and was an advisor to the Digital Health Cooperative Research Centre until the end of June 2026. Her previous Board non-executive director roles include Telstra Health, HeartWare Limited, Symbion Health Limited and Chair of Sydney Children Hospital Network. In December 2021, she retired from and was awarded Emeritus Professor by The University of Notre Dame Australia where she was Deputy Vice Chancellor, Enterprise & Partnerships and Dean, School of Medicine, Sydney for over ten years. Her prior experience has included being Group Executive and Chief Medical Officer for MBF and then Bupa Health and Care Services; CEO and later Chair of Research Australia; Managing Director of Total Health Enterprise Ltd; Partner in Health and Life Sciences for KPMG Australia; CEO of Westmead Hospital and Community Health Services; General Manager for the Royal Hospital for Women; and Head of Planning in NSW Health. Professor Bennett was awarded an Officer of the Order of Australia (AO) in the 2014 Australia Day Honours in recognition of her distinguished service to medicine and health care leadership. She is a member of the Risk Management Committee.

Ms Spargo worked in private practice and government, and as a director. She has been a director of both listed and unlisted companies for more than 20 years and is currently a director of the company Bapcor Limited (from March 2023). Ms Spargo also holds non-executive director roles with CIMIC Group Limited and Geelong Football Club Limited. Ms Spargo was previously a Non-executive Director of Fletcher Building Limited, Xenith IP Group Limited, Adairs Limited (from May 2015 to September 2024), Sigma Healthcare Limited (from December 2015 to February 2025) and the Future Fuels Cooperative Research Centre.

Ms Evans is an experienced non-executive director, business leader and corporate finance lawyer. Over a 35-year career, she has gained a range of commercial, business management, capital management, strategy and legal experience in the financial services, health, energy and infrastructure sectors. She was a corporate advisory partner at King & Wood Mallesons for more than 20 years and held key management positions at the firm including Managing Partner International in Hong Kong and Managing Partner, Practice in Sydney. Ms Wakefield Evans is currently a member of the Australia Future Fund Board of Guardians, and a Non-executive Director of Qube Holdings Limited, the Clean Energy Finance Corporation, the GO Foundation, The University of New South Wales Foundation Limited and the Cruising Yacht Club Australia. She is also Chair of MetLife Australia and a member of the Australian Government Takeovers Panel. Ms Wakefield Evans previous non-executive directorships have included Viva Energy Group Limited (until April 2026), Lendlease Group (until November 2024) and Macquarie Group Limited (until February 2024). In 2019 Ms Wakefield Evans was invited by the Australian Government to be a member of the Australian delegation to the United Nations Commission on the Status of Women. She is a member of Chief Executive Women, and in 2023 was appointed as a Member of the Order of Australia (AM) in recognition of service to business, the law, and diversity. In 2026, she won the AFR BOSS Director Excellence award.

Dr Giles initially practiced as a medical doctor. She moved to commercial pursuits which combined science, medicine and health. Dr Giles is currently Managing Director and Chief Executive Officer of OncoRes Medical (since 2017), which is developing novel imaging technology to improve cancer outcomes. She is also a Venture Partner at Brandon Capital Partners (since 2012), a venture capital firm dedicated to developing and supporting Australian life sciences businesses. She was previously an Investment Manager with Stone Ridge Ventures, a fund manager specializing in technology investment, and a Founding Director of the Australian Government National Reconstruction Fund Corporation. Dr Giles has start-up experience in medical apps, diagnostics and fitness devices and has served on the boards of private health care related technology companies. She is a member of the Curtin Commercialization Advisory Panel.

Dr Newcombe joined Sonic in 2017 and previously served as Chief Executive Officer of Douglass Hanly Moir Pathology. Dr Newcombe has experience in pathology, clinical medicine and healthcare management in both the public and private sectors. He is a member of the Risk Management Committee.

-

-